Hints and tips:
Related Special Reports
...WPP’s Ogilvy advertising agency is creating a division specialising in online “health influencers” to help pharmaceutical companies tap a trend towards personalised health and combat misinformation....
...It has also worked on drug development for US pharma company Johnson & Johnson, Danish biotech group Genmab and British biotech Iksuda therapeutics....
...Johnson & Johnson has struck a deal to buy medical device maker Shockwave Medical for $13.1bn, as the healthcare giant puts cash to work from the spin-off of its consumer health arm to pursue acquisitions...
...Johnson & Johnson has offered an improved $6.5bn settlement to tens of thousands of plaintiffs claiming that its talcum powder products caused ovarian cancer, in its latest attempt to draw a line under the...
...Johnson & Johnson had received scorn for executing the so-called Texas Two-Step bankruptcy strategy. The healthcare titan was facing thousands of claims about allegedly carcinogenic talcum powder....
...Roche, Johnson & Johnson and Denmark’s Genmab have all inked deals this year, following nearly $100bn of ADC-focused M&A and partnership transactions last year....
...company....
...These days, Lilly is the world’s most valuable drugmaker, after overtaking Johnson & Johnson last summer. Its $610bn market capitalisation makes it the ninth biggest company on the S&P 500....
...The deal comes as pharmaceutical companies are gathered in San Francisco for an annual industry conference this week, with GSK rivals Johnson & Johnson striking a $2bn deal to acquire an oncology biotech...
...“There’s a lot of biotech investors and big pharmaceutical companies sitting on the sidelines . . . they want to see what the commercial rollout looks like,” said Tim Schlidt, co-founder of Palo Santo, a...
...Investors were dismayed by the failed £50bn bid for GSK’s consumer healthcare arm, now Haleon, early last year....
...Johnson & Johnson joins the Merck, Bristol Myers Squibb and pharmaceutical lobby Pharmaceutical Research and Manufacturers of America in challenging the new law....
...The company joins Merck, Bristol Myers Squibb and the lobby group Pharmaceutical Research and Manufacturers of America in challenging the new law....
...Meanwhile, vaccine makers whose stocks were winners of the early pandemic period such as Pfizer, BioNTech, Moderna and Johnson & Johnson have been among the worst-performers in a year when the S&P 500 approached...
...Johnson & Johnson struck a $2bn deal to buy Ambrx Biopharma, which specialises in antibody-drug conjugates, one of the hottest areas in cancer treatment....
...Ginger Graham, a board member since 2010 and former chief of Amylin Pharmaceuticals, will fill the chief executive role while it searches for “a successor with deep healthcare experience”....
...In 2020, Pfizer spun off its generics business Upjohn, combining it with Mylan to form Viatris, while Johnson & Johnson, GSK, Pfizer and Novartis have all shed their consumer health businesses selling over-the-counter...
...The four pharmaceutical companies that part-funded the project — Amgen, AstraZeneca, GSK and Johnson & Johnson, — received nine months’ exclusive access to the data, which will now be made available to approved...
...Johnson & Johnson, one of the world’s largest healthcare companies, is facing thousands of lawsuits from people alleging they got cancer from using one of their oldest products: talc-based baby powder....
...and the Johnson & Johnson subsidiary Janssen Pharmaceuticals....
...The world’s biggest healthcare products company said on Tuesday it was unfortunate that it had to pay claimants for what it described as “baseless scientific claims” but noted that protracted litigation...
...Shares of Kenvue, the consumer arm of healthcare giant Johnson & Johnson, jumped on their first day of trading after an upsized initial public offering that marked the biggest US listing in almost 18 months...
...Other drugmakers including Merck, Bristol Myers Squibb, and Johnson & Johnson, as well as the US pharmaceutical lobby group, have already filed lawsuits against the reforms....
...This week it leapfrogged Johnson & Johnson and UnitedHealth to become the world’s most valuable drugmaker and healthcare company by market capitalisation....
International Edition